ReviewJournal of Alzheimer's disease reports2021
Protein and Imaging Biomarkers in the Eye for Early Detection of Alzheimer's Disease.
Review in Journal of Alzheimer's disease reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of virtual reality exercise on interventions for patients with Alzheimer's disease: A systematic review.Frontiers in psychiatry · 2022Pooled it
- Exploring Alzheimer Disease from a Retinal and Ocular Perspective.Biomedicines · 2026Review
- Visual Function in Alzheimer's Disease: Current Understanding and Potential Mechanisms Behind Visual Impairment.Journal of clinical medicine · 2025Review
- Glial fibrillary acidic protein in plasma and intraocular fluids and the correlation with cognitive function in patients with vitreoretinal disease.Scientific reports · 2025Article
- Potential Retinal Biomarkers in Alzheimer's Disease.International journal of molecular sciences · 2023Review
- The Eye as a Diagnostic Tool for Alzheimer's Disease.Life (Basel, Switzerland) · 2023Review
- Disruption of early visual processing in amyloid-positive healthy individuals and mild cognitive impairment.Alzheimer's research & therapy · 2023Article
- Proteostasis in aging-associated ocular disease.Molecular aspects of medicine · 2022Review
- Solving neurodegeneration: common mechanisms and strategies for new treatments.Molecular neurodegeneration · 2022Review
- Alzheimer's Disease Seen through the Eye: Ocular Alterations and Neurodegeneration.International journal of molecular sciences · 2022Review
- Sensing Using Light: A Key Area of Sensors.Sensors (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Alzheimer's disease (AD) is one of the most common causes of dementia worldwide. Although no formal curative therapy exists for the treatment of AD, considerable research has been performed to identify biomarkers for early detection of this disease, and thus improved subsequent management. Given that the eye can be examined and imaged non-invasively with relative ease, it has emerged as an exciting area of research for evidence of biomarkers and to aid in the early diagnosis of AD. This review explores the current understanding of both protein and retinal imaging biomarkers in the eye. Herein, primary findings in the literature regarding AD biomarkers associated with the lens, retina, and other ocular structures are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.